Dr Reddys Laboratories (RDY) Cash from Financing Activities (2009 - 2018)

Dr Reddys Laboratories (RDY) has reported Cash from Financing Activities for 9 consecutive years, with -$1.7 billion the latest figure, recorded in Q1 2018.

• Quarterly Cash from Financing Activities changed N/A year-over-year to -$1.7 billion in Q1 2018, while the trailing twelve-month figure through Mar 2018 was -$4.9 billion (changed N/A YoY) and the FY2026 annual result came in at $88.0 million, down 60.36% from the prior year.
• Cash from Financing Activities eased to -$1.7 billion in Q1 2018 per RDY's latest filing, from $2.2 billion in the prior quarter.
• Over the last five years, Cash from Financing Activities for RDY reached as high as $19.5 billion in Q3 2016 and fell as low as -$9.4 billion in Q3 2015.
• A 4-year average of -$150.1 million and a median of -$2.6 billion in 2015 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2016 — Cash from Financing Activities surged 307.35% — and 2017, when it tumbled 109.93%.
• Year by year, Cash from Financing Activities stood at -$3.3 billion in 2015, then dropped by 8.04% to -$3.5 billion in 2016, then soared by 163.72% to $2.2 billion in 2017, then slumped by 174.23% to -$1.7 billion in 2018.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$1.7 billion, $2.2 billion, and -$1.9 billion for Q1 2018, Q4 2017, and Q3 2017 respectively.